Company Overview - Zhuhai Rundu Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise established in 1999, located in Zhuhai, Guangdong Province. The company went public on January 5, 2018, on the Shenzhen Stock Exchange [2][3]. - The company specializes in drug research and development, production, and sales, focusing on chemical drug formulations, raw materials, and intermediates, with applications in cardiovascular, anti-infection, digestive, analgesic, and anesthetic treatments [2][3]. Product Development and Sales - The Class 1 innovative drug, Dexmedetomidine Hydrochloride Injection, submitted for registration in March 2024, is currently in the CDE drug approval sequence [4]. - The company’s subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., received a tobacco production license valid until June 30, 2028, enhancing its nicotine production capabilities. Sales of nicotine have significantly increased in the first three quarters of 2025 compared to the previous year, although this has not yet impacted overall performance [5]. - Sales of Rabeprazole Sodium Enteric-Coated Capsules have significantly declined due to inclusion in the national centralized procurement directory, affecting the company's performance in 2024 and the first half of 2025 [6][8]. Financial Performance - The decline in 2025 performance is attributed to changes in pharmaceutical industry policies and market conditions, particularly the national centralized procurement policy, leading to decreased sales and profit margins [8]. - The company aims to enhance profitability and competitiveness through cost reduction, efficiency improvements, and the implementation of ESG governance [8]. Production Capacity - The company has achieved a high capacity utilization rate, with a newly built oral solid dosage workshop designed for an annual capacity of 6 billion tablets, marking a significant upgrade in production capabilities [9][10]. - The subsidiary's designed annual capacity is 4,000 tons, currently in a ramp-up phase, with significant improvements compared to the previous year [10]. Future Directions - The company is focusing on the development of cardiovascular, digestive, anti-infection, and analgesic treatments, with plans to evaluate the expansion into new areas based on clinical needs and technological trends [10].

证券代码：002923 证券简称：润都股份 公告编号：2025-055 珠海润都制药股份有限公司 关于持股 5%以上股东减持计划期限届满暨实施结果的公告 本公司控股股东、实际控制人李希先生及其一致行动人陈新民先生保证向 本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 （2）本表中的"比例"为四舍五入后保留两位小数的结果。 2、股东及其一致行动人本次减持前后持股情况 | 股东名 | 股份性质 | 本次变动前持有股份 | | 本次变动后持有股份 | | | --- | --- | --- | --- | --- | --- | | 称 | | 股数（股） | 占总股本 | 股数（股） | 占总股本 | | | | | 比例（%） | | 比例（%） | | | 合计持有股份 | 100,865,992 | 30.12% | 94,041,612 | 28.08% | | 李希 | 其中：无限售条件股 | 100,865,992 | 30.12% | 94,041,612 | 28.08% | | | 有限售条件股 | 0 | 0.00% | 0 | 0.00% | | 陈新民 | 合 ...

Core Insights - On November 10, 2025, Rundu Co., Ltd. executed a block trade of 610,000 shares, amounting to 7.3322 million yuan, which represented 10.13% of the total trading volume for the day. The transaction price was 12.02 yuan, reflecting an 11.62% discount compared to the market closing price of 13.6 yuan [1] Summary by Category Trading Activity - The block trade involved a total of 610,000 shares at a price of 12.02 yuan per share [1] - The total transaction value was 7.3322 million yuan, accounting for 10.13% of the day's total trading volume [1] Buyer and Seller Information - The buyers included institutional trading desks from Donghai Securities and Huatai Securities, among others [2] - The sellers were primarily from Huaxi Securities, with multiple branches involved in the transaction [2]

Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), is currently in the drug registration review phase for its innovative drug, Sodium Deoxycorticosterone Injection, and is progressing normally despite inquiries about a pause in drug evaluation [2] Group 1 - The company confirmed that the Sodium Deoxycorticosterone Injection is still under review by the National Medical Products Administration of China [2] - The company will adhere to information disclosure regulations and will provide updates on any significant developments [2] - The inquiry from investors was regarding the reasons for the reported pause in drug evaluation, which the company clarified as not applicable to their situation [2]

Core Viewpoint - Rundu Co., Ltd. is currently in the drug registration review phase for its innovative drug, Dexmedetomidine Hydrochloride Injection, with the National Medical Products Administration of China, and is progressing normally. The company may consider expanding into overseas markets based on domestic market development and sales performance [1] Group 1 - The innovative drug Dexmedetomidine Hydrochloride Injection is under review by the National Medical Products Administration of China [1] - The company is actively progressing through the drug registration process [1] - Future expansion into overseas markets is a possibility depending on domestic market conditions [1]

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on November 6, with a total transaction volume of 2.431 billion yuan, highlighting notable trading in companies such as Zhongwei Company, CATL, and Bull Group [1]. Group 1: Trading Activity - A total of 65 stocks underwent block trading, with transaction amounts reaching 2.431 billion yuan [1]. - The top three companies by transaction volume were Zhongwei Company (321 million yuan), CATL (288 million yuan), and Bull Group (254 million yuan) [1]. - Among the stocks, 7 were traded at par value, 3 at a premium, and 55 at a discount [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were Yuchen Intelligent (18.21%), Beijing Bank (10.37%), and AVIC Chengfei (8.69%) [1]. - The stocks with the highest discount rates included Longzhu Technology (26.25%), Electric Alloy (24.03%), and Youfang Technology (21.97%) [1]. Group 3: Institutional Trading - The top institutional buy amounts were led by Zhongwei Company (299 million yuan), CATL (288 million yuan), and Zhongji Xuchuang (183 million yuan) [2]. - The leading institutional sell amounts were dominated by CATL (288 million yuan), Zijin Mining (217 million yuan), and Zhongji Xuchuang (183 million yuan) [2].

Summary of Key Points Core Viewpoint - On November 6, 2025, Rundu Co., Ltd. executed a block trade of 1.5445 million shares, amounting to 18.7039 million yuan, which represented 26.95% of the total trading volume for the day. The transaction price was 12.11 yuan, reflecting an 8.95% discount compared to the market closing price of 13.3 yuan [1]. Group 1: Trading Details - The block trade involved multiple transactions with a total volume of 154,450 shares at a price of 12.11 yuan per share [1]. - The total transaction value was 18.7039 million yuan, indicating significant trading activity on that day [1]. - The block trade accounted for 26.95% of the total trading volume, highlighting its impact on the market [1]. Group 2: Buyer and Seller Information - The buyers included various brokerage firms such as Donghai Securities and CITIC Securities, indicating institutional interest in the stock [2]. - The selling party was primarily Huaxi Securities, suggesting a potential shift in their investment strategy [2]. - Specific transaction volumes included 41.3 thousand shares for 500.14 thousand yuan and 80 thousand shares for 968.80 thousand yuan, showcasing diverse trading strategies among buyers [2].

证券代码：002923 证券简称：润都股份 公告编号：2025-054 珠海润都制药股份有限公司 2、本次权益变动前，公司控股股东、实际控制人李希先生及其一致行动人 陈新民先生合计持有公司股份 200,928,284 股，占公司总股本的 60.00%；本次 变动后，李希先生和陈新民先生合计持有公司股份 197,262,104 股，占公司总股 本的 58.90%。本次权益变动后导致李希先生和陈新民先生合计持有股份占公司 已发行股份的比例触及 1%的整数倍。 3、本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公 司治理结构及未来持续经营产生重大影响。 一、本次权益变动基本情况 珠海润都制药股份有限公司（以下简称"公司"或"润都股份"）于 2025 年 07 月 21 日披露《关于持股 5%以上股东减持股份预披露的公告》（公告编号： 2025-032），公司控股股东及实际控制人李希先生计划自公告之日起十五个交易 日后的三个月内（即 2025 年 08 月 11 日至 2025 年 11 月 10 日）通过集中竞价交 易、大宗交易方式减持公司股份合计不超过 10,046,797 股，即不超过公司总股 本 ...

Core Viewpoint - Rundu Co., Ltd. announced the election of Ms. Wang Yongchao as the employee representative director of the fifth board of directors during the employee representative meeting scheduled for October 23, 2025 [2] Summary by Categories - **Company Announcement** - Rundu Co., Ltd. will hold an employee representative meeting on October 23, 2025 [2] - Ms. Wang Yongchao has been nominated to serve as the employee representative director [2]

珠海润都制药股份有限公司 珠海润都制药股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规、 规范性文件及《公司章程》的相关规定，为进一步完善珠海润都制药股份有限公 司（以下简称"公司"）的治理结构，保证公司董事会的规范运作，公司于 2025 年 10 月 23 日召开职工代表大会，选举王永超女士（简历详见附件）担任公司第 五届董事会职工代表董事（以下简称"职工董事"），王永超女士将与公司 2023 年第一次临时股东大会、2024 年年度股东大会选举产生的七名非职工董事组成 公司第五届董事会，任期与第五届董事会任期一致。公司对选举结果进行了公示， 2025 年 10 月 30 日公示期满无异议。 上述职工董事符合《公司法》、《公司章程》中有关董事任职的资格和条件。 本次选举第五届董事会职工董事事项完成后，董事会中兼任公司高级管理人员以 及由职工代表担任的董事人数总计不超过公司董事总数 ...